Matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA

(4:1econd)

Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCL

(59)

Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLL

(3:20)

Everything you need to know about matching adjusted indirect comparisons

(42:5)

Propensity score matching methodology: why and how it is used

(3:3)

Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma

(1:44)

Matched-adjusted comparison of liso-cel versus axi-cel for the second-line treatment of R/R LBCL

(2:18)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

(3:56)

HSN | Home Sweet Home with Natasha - First Big Sale of the Year 01.20.2025 - 11 AM

(1:)

Introduction to Indirect Treatment Comparison Part 1

(5:29)

Indirect Treatment Comparisons and Network Meta-analyses for Managers and Directors

(7:18)

R for HTA 2022 Workshop - Erin Barker

(22:45)

Overview of different indirect comparison approaches and methods

(40:2)

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

(2:16)

Propensity scores: Everything you need to know in 5min

(6:49)

CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD

(20:1econd)

Indirect Treatment Comparison Shows Momelotinib Has ‘Favorable’ Safety in Myelofibrosis

(5:25)

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma

(1:27)

MAIC of zanubrutinib and venetoclax + ibrutinib in treatment-naïve CLL

(1:3)

IDWSDS 2023 - S10: A Simulation Study to Explore the Effect of Repeated Use of Individual Patient...

(22:15)